前列腺癌患者血清胱抑素C水平与临床评分相关性研究

Correlation between serum Cystatin C level and clinical score in patients with prostate cancer

目的:探讨前列腺癌患者血清胱抑素C(Cystatin C)水平与Gleason评分分数、总前列腺特异性抗原(tPSA)水平及临床分期的相关性。方法:纳入我院前列腺癌患者共142例(前列腺癌组),建立临床资料数据库,对病理切片应用Gleason分级系统对前列腺癌进行组织学分级,使用25.0版本的SPSS软件对数据进行统计学分析,应用t检验对计量资料进行比较。对于不同Gleason评分、不同临床分期、不同tPSA水平的前列腺癌患者与血清Cystatin C水平的相关关系采用Spearman等级相关性检验;对血清Cystatin C含量与年龄的相关性采用Pearson相关分析。以P<0.05为差异有统计学意义。结果:142例前列腺癌组患者Cystatin C水平高于166例健康对照组,差异有统计学意义[(1.27±0.55) mg/L vs.(0.94±0.18) mg/L,P<0.001]。在59例有Gleason评分的前列腺癌患者中,血清Cystatin C含量在Gleason评分各组中的差异无统计学意义(P>0.05)。45例已分期前列腺癌患者中,血清Cystatin C水平与前列腺癌临床分期呈正相关(r=0.386,P<0.01),Cystatin C含量越高,临床分期越晚。在142例已测tPSA水平前列腺癌患者中,经分析显示,前列腺癌Cystatin C水平与tPSA水平无显著相关性,且差异无统计学意义(r=0.098,P>0.05)。结论:血清Cystatin C水平对于前列腺癌的早期诊断及临床分期具有重要意义。

Objective: To investigate the relationship between serum Cystatin C level and Gleason score, clinical stage and tPSA level in patients with prostate cancer. Methods: A total of 142 patients with prostate cancer in our hospital were enrolled in this study, and a clinical information database was established. The Gleason grading system was used to analyze the histological grade of prostate cancer. The statistical software SPSS 25.0 was used for statistical analysis. The data were compared by t test. Correlation between serum Cystatin C levels and tPSA levels, different Gleason scores and different clinical stages of prostate cancer were performed using Spearman rank correlation analysis. The correlation between serum Cystatin C content and age was analyzed by Pearson correlation. P<0.05 suggested that the difference was statistically significant. Results: The level of Cystatin C(1.27±0.55) mg/L in 142 patients with prostate cancer was higher than that in 166 healthy subjects(0.94±0.18) mg/L, and the difference was statistically significant(P<0.001). There was no significant difference in serum Cystatin C levels among the different Gleason scores in 59 patients with prostate cancer(P>0.05). In 45 patients with staged prostate cancer, serum Cystatin C level was positively correlated with clinical stage of prostate cancer(r=0.386, P<0.01). The higher the Cystatin C content, the later the clinical stage. In 142 patients with tPSA level prostate cancer, analysis showed that there was no significant correlation between the level of Cystatin C and tPSA in prostate cancer, and the difference was not statistically significant(r=0.098, P>0.05). Conclusion: Serum Cystatin C level is of great significance for early diagnosis and clinical staging of prostate cancer.